ResearcherChinese PLA General HospitalActive in the last 2 years
Qianqian Wang
Matched on ORCID iD 0009-0005-9308-0584; OpenAlex author ID A5115594555. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 4
- The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Co-author DOI 10.1186/s12885-025-14262-1↗
- Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. Co-author DOI 10.1186/s12885-025-14601-2↗
- Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy. Co-author DOI 10.3390/cancers15082213↗
- Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis. Co-author PMID 26379850↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yang Feng Wu · 2 shared papers, 2025 · strength 0.50
- Paper The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients un… DOI 10.1186/s12885-025-14262-1↗
- Paper Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. DOI 10.1186/s12885-025-14601-2↗
- Jishu Wei · 2 shared papers, 2025 · strength 0.50
- Paper The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients un… DOI 10.1186/s12885-025-14262-1↗
- Paper Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. DOI 10.1186/s12885-025-14601-2↗
- Dong Xu · 2 shared papers, 2025 · strength 0.50
- Paper The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients un… DOI 10.1186/s12885-025-14262-1↗
- Paper Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. DOI 10.1186/s12885-025-14601-2↗
- Min Tu · 2 shared papers, 2025 · strength 0.50
- Paper The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients un… DOI 10.1186/s12885-025-14262-1↗
- Paper Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. DOI 10.1186/s12885-025-14601-2↗
- Kai Zhang · 1 shared paper, 2025 · strength 0.26
- Yi Miao · 1 shared paper, 2025 · strength 0.26
- Kuirong Jiang · 1 shared paper, 2025 · strength 0.26
- Wentao Gao · 1 shared paper, 2025 · strength 0.25
- Junli Wu · 1 shared paper, 2025 · strength 0.25
- Kuirong Jiang · 1 shared paper, 2025 · strength 0.25
- Biyang Cao · 1 shared paper, 2023 · strength 0.19
- Jing Wang · 1 shared paper, 2023 · strength 0.19
- Letian Zhang · 1 shared paper, 2023 · strength 0.19
- Hong Yu Zheng · 1 shared paper, 2015 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.